Precision Medicine

Spurred by celebrity stories and a viral campaign, the Webby-winning Know Your Lemons app offers personalized risk scores and private screening plans.

A landmark conference merges top organizations to accelerate research on retinal diseases, from gene editing to AI, offering new hope for millions worldwide.

A groundbreaking knee implant offers Hoosiers a new joint-preserving option, bridging the gap between conservative care and total knee replacement.

A new alcohol-free, no-refrigeration blood pressure liquid aims to transform daily treatment for children, reflecting a key industry shift.

Astellas and Pfizer's PADCEV-Keytruda combo, showing a 47% drop in recurrence risk, earns FDA Priority Review, offering new hope for bladder cancer patients.

A new bispecific antibody, EPI-326, enters human trials, hoping its unique tissue-selective degradation can defeat EGFR-driven cancers where others fail.

New preclinical data reveals a novel drug, rinzimetostat, may overcome treatment resistance in prostate cancer by targeting a unique molecular switch.

A new gene therapy that reprograms cancer cells into immune activators shows major promise, blending personalized treatment with off-the-shelf convenience.

Interim trial data shows IPH5201 plus durvalumab yields pathological complete response rates up to 50%, far surpassing current standards for resectable NSCLC.

Interim study results suggest a common food product may significantly enhance the effectiveness of modern cancer treatments, heralding a new era of care.

A surprise $5 million pledge for glaucoma research highlights a gala honoring philanthropist Daria Barry, patient advocate Hillary Golden, and music icon Nile Rodgers.

New guidelines advise biennial screening for women 50-74 and caution for others, a move that has drawn sharp criticism from other medical bodies.

At AACR 2026, CREATE Medicines debuts its RetroT platform, an all-RNA system for stable gene delivery that avoids viral vectors and reshapes cell therapy.

Byondis presents two novel ADC platforms at AACR 2026, aiming to solve drug resistance and offer hope for patients unresponsive to immunotherapy.

With $36M secured, Orthogon Therapeutics is advancing a first-in-class oral drug for BK virus, offering a new lifeline for transplant patients.

For over a decade, Wake Radiology has backed the Komen Race for the Cure, funding research and expanding access to life-saving breast cancer screenings.

New data reveals Mapi Pharma's long-acting GA Depot stabilizes disability in both relapsing and progressive MS, poised for a 2027 European launch.

Patients, doctors, and researchers unite for a grueling ride across Iceland, raising funds and hope for a future free from multiple myeloma.

A new oral drug candidate for lupus and RA emerges as Totus Medicines uses its AI platform to rapidly develop a first-in-class inhibitor for the elusive IRF5 protein.

A novel drug for a debilitating stomach disorder is set for a major reveal, offering hope to millions with limited and often risky treatment options.